Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Koenig (NPI 1750335196)

Field	Value
Entity Type	Individual
Organization	Christopher Koenig
Address	12800 Metcalf Ave
City	Overland Park
State	KS
ZIP	66213
Taxonomy	Rheumatology Physician
NPI Enumerated	May 20, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

CHRISTOPHER KOENIG is a Rheumatology Physician in OVERLAND PARK, KS with an NPI enumerated on 2006-05-20 (~20 years ago). His Medicare lifetime revenue is $2.3M and there is no Medicaid billing on file (none below), indicating this profile is effectively single-payer Medicare in scale and exposure.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 52.9% of his total Medicare revenue, driven by J0129 ($485.4K, 21.4%), J3262 ($363.2K, 16.0%), and J9312 ($349.5K, 15.4%). This concentration shows a small number of biologic drug codes dominate his Medicare receipts.

The code mix is characteristic of an infusion/biologic-focused rheumatology practice: the top revenue drivers are injectable biologics (J0129 abatacept, J3262 tocilizumab, J9312 rituximab) and the payer descriptors and CPTs for infusion administration (96413, 96415, 96365) appear throughout the top-25. Together these codes suggest the practice operates an infusion service that administers physician-supervised biologic therapies rather than relying primarily on office-only management.

Competitive standing for the principal biologics is above average but not dominant nationally: J9312 ranks #46 of 317 providers (86th percentile; typical, unremarkable volume), J3262 ranks #119 of 618 (81th percentile; typical, unremarkable volume), and J0129 ranks #275 of 1221 (77th percentile; typical, unremarkable volume). These rankings indicate a stronger-than-average national presence on certain biologic agents, with J9312 showing the strongest relative position among peers.

Procedural and visit-level activity shows concentrated, higher-complexity throughput: 99214 (898 claims, $77.2K, 3.4% of Medicare revenue) ranks in the 97th percentile and is described as notably above typical national volume, while infusion administration CPTs 96413 (638 claims, $61.2K, 2.7%) and add-on 96415 (369 claims, $7.7K, 0.3%) are also described as notably above typical national volume. This combination of high-complexity E/M visits and above-typical infusion administration supports the view of a practice managing complex, time-intensive infusion encounters.

Routine laboratory and monitoring codes appear consistently but at modest revenue share, supporting chronic disease management activities: 85025 (836 claims, $6.7K, 0.3%), 80053 (501 claims, $5K, 0.2%), 86140 (829 claims, $4.1K, 0.2%), and 82306 (90 claims, $2.6K, 0.1%) are present in the top-25 and are described as typical, unremarkable volume. These lab services align with ongoing monitoring needs for patients on biologic therapies.

Payer mix and business risk are concentrated in Medicare: with $2.3M in Medicare revenue and no Medicaid billed (none below), the provider’s revenue is effectively single-payer, which concentrates reimbursement exposure to Medicare policy changes and payer fee schedules. Analysts should treat Medicaid-driven strategies or state-level Medicaid comparisons as not applicable given the absence of Medicaid claims.

Service-line asymmetry suggests a focus on established patient management and infusions rather than new patient high-complexity intake: 99205 (19 claims, $2.8K, 0.1%) ranks in the 34th percentile and is described as typical, unremarkable volume, indicating relatively limited new-patient, highest-complexity visit volume compared with the higher 99214 volume for established patients. Similarly, some biologic codes like J1602 (9.2K claims, $101.2K, 4.5%) rank at the 30th percentile and are labeled typical, unremarkable volume, showing variation in which infusion agents are emphasized compared with national peers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	14,280	$30	$485.4K
J3262	Injection, tocilizumab, 1 mg	72,640	$10	$363.2K
J9312	Injection, rituximab, 10 mg	5,730	$60	$349.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	7,280	$40	$262.1K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	51,600	$1	$206.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,440	$30	$167.4K
J0897	Injection, denosumab, 1 mg	6,060	$20	$109.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	9,200	$10	$101.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	900	$90	$77.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$100	$61.2K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Christopher Koenig — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	20	8,000	$30	$291.5K
J3262	2	10	60,820	$1	$243K
J0717	6	10	51,600	$1	$200.4K
J1569	1	10	6,320	$40	$195.9K
J9312	2	10	2,500	$60	$194.7K
J1602	15	20	14,360	$10	$167.7K
J1745	3	20	3,110	$30	$96.9K
J0897	32	180	2,160	$20	$81.5K
82306	34	160	40	$30	$27.1K
96413	14	80	80	$90	$26.3K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Koenig, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michael Smith	CO	Rheumatology Physician	$2M	$0
Kalista Engelman	MO	Rheumatology Physician	$1.7M	$0
Julian Magadan	MO	Rheumatology Physician	$1.7M	$0
Tina Shah	MO	Rheumatology Physician	$1.6M	$0
Kent Huston	MO	Rheumatology Physician	$1.5M	$0
Shirley Wang	KS	Rheumatology Physician	$1.2M	$0
Ann Warner	MO	Rheumatology Physician	$911.8K	$0
Travis Sifers	MO	Allergy & Immunology (Internal Medicine) Physician	$614.2K	$0
Jeremy Sharp	KS	Rheumatology Physician	$433.9K	$0
Zachary Jacobs	MO	Allergy & Immunology Physician	$416.2K	$0

Nearby Providers

Other providers in the same ZIP code as Christopher Koenig, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Pinnacle Regional Hospital, Inc.	KS	General Acute Care Hospital	$0	$12.8M
Rose Estates	KS	Assisted Living Facility	$0	$4.4M
Deer Creek Surgery Center, LLC	KS	Ambulatory Surgical Clinic/Center	$1.8M	$0
Saint Lukes South Hospital, Inc.	KS	General Acute Care Hospital	$0	$1.6M
Keith Warren	KS	Ophthalmology Physician	$1.1M	$8.4K
Mep Kansas LLC	KS	Emergency Medicine Physician	$0	$1.1M
Clare Roewe	KS	Family Nurse Practitioner	$952.9K	$0
Saint Lukes South Surgery Center LLC	KS	Ambulatory Surgical Clinic/Center	$949.8K	$0
Advanced Radiology Consultants Of Kansas City, PA	KS	Diagnostic Radiology Physician	$0	$840.3K
Aruna Baratham	KS	Rheumatology Physician	$768.3K	$0

Christopher Koenig — Billing Profile & Reimbursement Data

Sign up for Christopher Koenig — Billing Profile & Reimbursement Data policy alerts

Christopher Koenig — Billing Profile & Reimbursement Data

Sign up for Christopher Koenig — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References